HC Wainwright Issues Positive Forecast for Sensus Healthcare (NASDAQ:SRTS) Stock Price

Sensus Healthcare (NASDAQ:SRTS) had its price objective upped by analysts at HC Wainwright from $10.00 to $11.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 43.98% from the stock’s current price.

Separately, Maxim Group lifted their target price on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday.

Sensus Healthcare Stock Up 4.8 %

Shares of SRTS stock opened at $7.64 on Monday. The company has a market capitalization of $125.22 million, a P/E ratio of 13.40 and a beta of 1.04. Sensus Healthcare has a 12-month low of $2.02 and a 12-month high of $8.29. The firm has a 50-day moving average price of $6.37 and a 200 day moving average price of $5.95.

Institutional Trading of Sensus Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Truvestments Capital LLC acquired a new position in Sensus Healthcare during the 3rd quarter worth about $32,000. Chapin Davis Inc. bought a new position in shares of Sensus Healthcare in the second quarter worth about $53,000. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare during the second quarter worth approximately $95,000. Cubist Systematic Strategies LLC bought a new stake in shares of Sensus Healthcare during the second quarter valued at approximately $156,000. Finally, Hillsdale Investment Management Inc. bought a new stake in shares of Sensus Healthcare during the first quarter valued at approximately $155,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.